150 related articles for article (PubMed ID: 21734411)
41. Phase II trial of mitoguazone in patients with refractory germ cell tumors.
Chun H; Bosl GJ
Cancer Treat Rep; 1985 Apr; 69(4):461-2. PubMed ID: 2986835
[No Abstract] [Full Text] [Related]
42. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
43. Activity of thalidomide in patients with platinum-refractory germ-cell tumours.
Rick O; Braun T; Siegert W; Beyer J
Eur J Cancer; 2006 Aug; 42(12):1775-9. PubMed ID: 16765039
[TBL] [Abstract][Full Text] [Related]
44. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Hlavatá Z; Mego M; Recková M; Koza I
Neoplasma; 2005; 52(6):497-501. PubMed ID: 16284696
[TBL] [Abstract][Full Text] [Related]
45. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours.
Steiner H; Müller T; Gozzi C; Akkad T; Bartsch G; Berger AP
BJU Int; 2006 Aug; 98(2):349-52. PubMed ID: 16626306
[TBL] [Abstract][Full Text] [Related]
46. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of daily oral etoposide in refractory germ cell tumors.
Miller JC; Einhorn LH
Semin Oncol; 1990 Feb; 17(1 Suppl 2):36-9. PubMed ID: 2154858
[TBL] [Abstract][Full Text] [Related]
48. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
[TBL] [Abstract][Full Text] [Related]
49. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
50. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
51. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
Kondagunta GV; Bacik J; Bajorin D; Dobrzynski D; Sheinfeld J; Motzer RJ; Bosl GJ
J Clin Oncol; 2005 Dec; 23(36):9290-4. PubMed ID: 16361627
[TBL] [Abstract][Full Text] [Related]
52. Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors.
Jain A; Brames MJ; Vaughn DJ; Einhorn LH
Am J Clin Oncol; 2014 Oct; 37(5):450-3. PubMed ID: 23388561
[TBL] [Abstract][Full Text] [Related]
53. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
[TBL] [Abstract][Full Text] [Related]
54. Outcomes following surgery for primary mediastinal nonseminomatous germ cell tumors in the cisplatin era.
Kesler KA; Stram AR; Timsina LR; Turrentine MW; Brown JW; Einhorn LH
J Thorac Cardiovasc Surg; 2021 Jun; 161(6):1947-1959.e1. PubMed ID: 32446546
[TBL] [Abstract][Full Text] [Related]
55. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.
Besse B; Grunenwald D; Fléchon A; Caty A; Chevreau C; Culine S; Théodore C; Fizazi K
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):448-52. PubMed ID: 19185168
[TBL] [Abstract][Full Text] [Related]
56. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
[TBL] [Abstract][Full Text] [Related]
57. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.
Feldman DR; Kondagunta GV; Ginsberg MS; Ishill N; Patil S; Cestaro J; Obbens E; Sheinfeld J; Bosl GJ; Motzer RJ
Invest New Drugs; 2007 Oct; 25(5):487-90. PubMed ID: 17520176
[TBL] [Abstract][Full Text] [Related]
58. Extragonadal germ cell tumors: relation to testicular neoplasia and management options.
Bokemeyer C; Hartmann JT; Fossa SD; Droz JP; Schmol HJ; Horwich A; Gerl A; Beyer J; Pont J; Kanz L; Nichols CR; Einhorn L
APMIS; 2003 Jan; 111(1):49-59; discussion 59-63. PubMed ID: 12752235
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
[TBL] [Abstract][Full Text] [Related]
60. Management of extragonadal germ-cell tumors and the significance of bilateral testicular biopsies.
Daugaard G; Rørth M; von der Maase H; Skakkebaek NE
Ann Oncol; 1992 Apr; 3(4):283-9. PubMed ID: 1327076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
